Prevention of P. Vivax Malaria During Pregnancy in Bolivia

• Status: Withdrawn
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine which, between weekly prophylaxis or malaria attack treatment, both by chloroquine, is the most appropriate way to protect women and foetus from P. vivax malaria infection during pregnancy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Institut de Recherche pour le Developpement
• Collaborators: Instituto Nacional de Laboratorios de Salud (INLASA); Ministry of Health, Bolivia; Pan American Health Organization
• Treatments: Chloroquine; Chloroquine diphosphate

Criteria

Inclusion Criteria:

• Pregnancy between 4 to 36 weeks of gestation

• Intention to deliver at the maternity clinics

• Residence near the maternity clinics

• Written informed consent (parents or tutors if aged<18 years)

Exclusion Criteria:

• Pregnancy prior to 4 weeks or after 36 weeks of gestation

• Allergy to chloroquine

• Clinical signs of hepatic or renal alteration

• Inability to take drugs by oral route

• Presence of effective uterine contractions